Dominari (DOMH) Competitors

$3.32 -0.53 (-13.77%)

Closing price 04:00 PM Eastern

Extended Trading

$3.48 +0.17 (+4.97%)

As of 05:23 PM Eastern

DOMH vs. ACHV, CDXS, SABS, AGEN, and FBIO

Should you buy Dominari stock or one of its competitors? MarketBeat compares Dominari with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Dominari include Achieve Life Sciences (ACHV), Codexis (CDXS), SAB Biotherapeutics (SABS), Agenus (AGEN), and Fortress Biotech (FBIO). These companies are all part of the "biotechnology" industry.

How does Dominari compare to Achieve Life Sciences?

Dominari (NASDAQ:DOMH) and Achieve Life Sciences (NASDAQ:ACHV) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, analyst recommendations, profitability and valuation.

Achieve Life Sciences has a consensus price target of $14.67, indicating a potential upside of 177.25%. Given Achieve Life Sciences' stronger consensus rating and higher possible upside, analysts clearly believe Achieve Life Sciences is more favorable than Dominari.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dominari	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Achieve Life Sciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Achieve Life Sciences had 25 more articles in the media than Dominari. MarketBeat recorded 29 mentions for Achieve Life Sciences and 4 mentions for Dominari. Dominari's average media sentiment score of 0.62 beat Achieve Life Sciences' score of 0.53 indicating that Dominari is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dominari	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Achieve Life Sciences	4 Very Positive mention(s)	0 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Achieve Life Sciences has a net margin of 0.00% compared to Dominari's net margin of -31.37%. Dominari's return on equity of -167.91% beat Achieve Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dominari	-31.37%	-167.91%	-138.74%
Achieve Life Sciences	N/A	-193.49%	-111.88%

42.5% of Dominari shares are owned by institutional investors. Comparatively, 33.5% of Achieve Life Sciences shares are owned by institutional investors. 55.3% of Dominari shares are owned by insiders. Comparatively, 3.0% of Achieve Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Dominari has higher revenue and earnings than Achieve Life Sciences. Achieve Life Sciences is trading at a lower price-to-earnings ratio than Dominari, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dominari	$123.10M	0.61	-$22.43M	-$3.88	N/A
Achieve Life Sciences	N/A	N/A	-$54.65M	-$1.12	N/A

Dominari has a beta of 0.69, indicating that its stock price is 31% less volatile than the broader market. Comparatively, Achieve Life Sciences has a beta of 2.25, indicating that its stock price is 125% more volatile than the broader market.

Summary

Achieve Life Sciences beats Dominari on 9 of the 16 factors compared between the two stocks.

How does Dominari compare to Codexis?

Codexis (NASDAQ:CDXS) and Dominari (NASDAQ:DOMH) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation.

78.5% of Codexis shares are owned by institutional investors. Comparatively, 42.5% of Dominari shares are owned by institutional investors. 3.5% of Codexis shares are owned by insiders. Comparatively, 55.3% of Dominari shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Codexis had 1 more articles in the media than Dominari. MarketBeat recorded 5 mentions for Codexis and 4 mentions for Dominari. Dominari's average media sentiment score of 0.62 beat Codexis' score of -0.14 indicating that Dominari is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Codexis	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
Dominari	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Codexis currently has a consensus target price of $5.00, indicating a potential upside of 103.25%. Given Codexis' stronger consensus rating and higher probable upside, equities research analysts clearly believe Codexis is more favorable than Dominari.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Codexis	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Dominari	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Codexis has a beta of 2.52, indicating that its stock price is 152% more volatile than the broader market. Comparatively, Dominari has a beta of 0.69, indicating that its stock price is 31% less volatile than the broader market.

Dominari has higher revenue and earnings than Codexis. Codexis is trading at a lower price-to-earnings ratio than Dominari, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Codexis	$78.09M	2.86	-$43.97M	-$0.37	N/A
Dominari	$123.10M	0.61	-$22.43M	-$3.88	N/A

Dominari has a net margin of -31.37% compared to Codexis' net margin of -40.97%. Codexis' return on equity of -68.09% beat Dominari's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Codexis	-40.97%	-68.09%	-23.72%
Dominari	-31.37%	-167.91%	-138.74%

Summary

Codexis beats Dominari on 10 of the 16 factors compared between the two stocks.

How does Dominari compare to SAB Biotherapeutics?

Dominari (NASDAQ:DOMH) and SAB Biotherapeutics (NASDAQ:SABS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, media sentiment, valuation, profitability and analyst recommendations.

SAB Biotherapeutics has lower revenue, but higher earnings than Dominari. SAB Biotherapeutics is trading at a lower price-to-earnings ratio than Dominari, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dominari	$123.10M	0.61	-$22.43M	-$3.88	N/A
SAB Biotherapeutics	$1.32M	142.81	$13.27M	-$2.32	N/A

In the previous week, SAB Biotherapeutics had 15 more articles in the media than Dominari. MarketBeat recorded 19 mentions for SAB Biotherapeutics and 4 mentions for Dominari. SAB Biotherapeutics' average media sentiment score of 0.73 beat Dominari's score of 0.62 indicating that SAB Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dominari	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
SAB Biotherapeutics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

SAB Biotherapeutics has a consensus price target of $11.00, suggesting a potential upside of 197.30%. Given SAB Biotherapeutics' stronger consensus rating and higher probable upside, analysts plainly believe SAB Biotherapeutics is more favorable than Dominari.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dominari	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
SAB Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Dominari has a beta of 0.69, indicating that its share price is 31% less volatile than the broader market. Comparatively, SAB Biotherapeutics has a beta of 0.55, indicating that its share price is 45% less volatile than the broader market.

42.5% of Dominari shares are held by institutional investors. Comparatively, 7.8% of SAB Biotherapeutics shares are held by institutional investors. 55.3% of Dominari shares are held by insiders. Comparatively, 25.1% of SAB Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

SAB Biotherapeutics has a net margin of 0.00% compared to Dominari's net margin of -31.37%. SAB Biotherapeutics' return on equity of -0.29% beat Dominari's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dominari	-31.37%	-167.91%	-138.74%
SAB Biotherapeutics	N/A	-0.29%	-0.25%

Summary

SAB Biotherapeutics beats Dominari on 12 of the 17 factors compared between the two stocks.

How does Dominari compare to Agenus?

Dominari (NASDAQ:DOMH) and Agenus (NASDAQ:AGEN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, media sentiment, earnings, risk, institutional ownership and valuation.

In the previous week, Agenus had 12 more articles in the media than Dominari. MarketBeat recorded 16 mentions for Agenus and 4 mentions for Dominari. Dominari's average media sentiment score of 0.62 beat Agenus' score of -0.01 indicating that Dominari is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dominari	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Agenus	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

42.5% of Dominari shares are held by institutional investors. Comparatively, 61.5% of Agenus shares are held by institutional investors. 55.3% of Dominari shares are held by insiders. Comparatively, 5.5% of Agenus shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Dominari has a beta of 0.69, indicating that its share price is 31% less volatile than the broader market. Comparatively, Agenus has a beta of 1.6, indicating that its share price is 60% more volatile than the broader market.

Agenus has a consensus price target of $14.50, indicating a potential upside of 305.03%. Given Agenus' stronger consensus rating and higher possible upside, analysts plainly believe Agenus is more favorable than Dominari.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dominari	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Agenus	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Agenus has lower revenue, but higher earnings than Dominari. Dominari is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dominari	$123.10M	0.61	-$22.43M	-$3.88	N/A
Agenus	$114.20M	1.31	$120K	$1.59	2.25

Agenus has a net margin of 50.49% compared to Dominari's net margin of -31.37%. Agenus' return on equity of -31.66% beat Dominari's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dominari	-31.37%	-167.91%	-138.74%
Agenus	50.49%	-31.66%	42.71%

Summary

Agenus beats Dominari on 13 of the 16 factors compared between the two stocks.

How does Dominari compare to Fortress Biotech?

Dominari (NASDAQ:DOMH) and Fortress Biotech (NASDAQ:FBIO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, earnings, valuation, institutional ownership, analyst recommendations, dividends and risk.

Fortress Biotech has a net margin of 10.77% compared to Dominari's net margin of -31.37%. Fortress Biotech's return on equity of -41.20% beat Dominari's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dominari	-31.37%	-167.91%	-138.74%
Fortress Biotech	10.77%	-41.20%	-11.53%

In the previous week, Fortress Biotech had 2 more articles in the media than Dominari. MarketBeat recorded 6 mentions for Fortress Biotech and 4 mentions for Dominari. Fortress Biotech's average media sentiment score of 0.81 beat Dominari's score of 0.62 indicating that Fortress Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dominari	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fortress Biotech	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Fortress Biotech has lower revenue, but higher earnings than Dominari. Fortress Biotech is trading at a lower price-to-earnings ratio than Dominari, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dominari	$123.10M	0.61	-$22.43M	-$3.88	N/A
Fortress Biotech	$63.26M	1.27	$6.82M	-$0.13	N/A

Fortress Biotech has a consensus target price of $17.00, suggesting a potential upside of 605.39%. Given Fortress Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Fortress Biotech is more favorable than Dominari.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dominari	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Fortress Biotech	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Dominari has a beta of 0.69, meaning that its share price is 31% less volatile than the broader market. Comparatively, Fortress Biotech has a beta of 1.16, meaning that its share price is 16% more volatile than the broader market.

42.5% of Dominari shares are owned by institutional investors. Comparatively, 96.5% of Fortress Biotech shares are owned by institutional investors. 55.3% of Dominari shares are owned by company insiders. Comparatively, 28.5% of Fortress Biotech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Fortress Biotech beats Dominari on 13 of the 16 factors compared between the two stocks.

Get Dominari News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DOMH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DOMH vs. The Competition

Export

Metric	Dominari	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$75.07M	$2.98B	$6.23B	$12.27B
Dividend Yield	N/A	1.96%	2.80%	5.35%
P/E Ratio	-0.82	17.97	20.14	25.23
Price / Sales	0.61	258.99	542.44	73.19
Price / Cash	N/A	57.78	43.26	56.33
Price / Book	0.78	4.29	9.81	6.90
Net Income	-$22.43M	$72.19M	$3.56B	$333.88M
7 Day Performance	-8.79%	-2.92%	0.33%	0.04%
1 Month Performance	8.50%	-3.11%	-0.98%	1.74%
1 Year Performance	-40.82%	40.55%	36.19%	32.64%

Dominari Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DOMH Dominari	0.9015 of 5 stars	$3.32 -13.8%	N/A	-33.8%	$75.07M	$123.10M	N/A	4	Gap Down
ACHV Achieve Life Sciences	2.9716 of 5 stars	$4.56 +3.9%	$14.67 +221.6%	+133.5%	$233.70M	N/A	N/A	20	Trending News Earnings Report Analyst Revision Gap Down
CDXS Codexis	2.9539 of 5 stars	$2.75 +9.6%	$5.00 +81.8%	+4.0%	$228.15M	$70.39M	N/A	250	Gap Down
SABS SAB Biotherapeutics	3.937 of 5 stars	$3.68 -0.3%	$10.50 +185.3%	+110.3%	$188.01M	$1.32M	N/A	140	Earnings Report Analyst Forecast Analyst Revision
AGEN Agenus	1.9623 of 5 stars	$4.17 +3.7%	$14.50 +247.7%	+3.2%	$154.36M	$114.20M	N/A	440	Trending News Earnings Report Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DOMH) was last updated on 5/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Dominari (DOMH) Competitors

DOMH vs. ACHV, CDXS, SABS, AGEN, and FBIO

How does Dominari compare to Achieve Life Sciences?

Summary

How does Dominari compare to Codexis?

Summary

How does Dominari compare to SAB Biotherapeutics?

Summary

How does Dominari compare to Agenus?

Summary

How does Dominari compare to Fortress Biotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DOMH vs. The Competition

Dominari Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Dominari (DOMH) Competitors

DOMH vs. ACHV, CDXS, SABS, AGEN, and FBIO

How does Dominari compare to Achieve Life Sciences?

Do analysts rate DOMH or ACHV?

Does the media prefer DOMH or ACHV?

Is DOMH or ACHV more profitable?

Do institutionals & insiders believe in DOMH or ACHV?

Which has stronger valuation and earnings, DOMH or ACHV?

Which has more risk & volatility, DOMH or ACHV?

Summary

How does Dominari compare to Codexis?

Do institutionals and insiders have more ownership in CDXS or DOMH?

Does the media refer more to CDXS or DOMH?

Do analysts recommend CDXS or DOMH?

Which has more volatility and risk, CDXS or DOMH?

Which has stronger valuation & earnings, CDXS or DOMH?

Is CDXS or DOMH more profitable?

Summary

How does Dominari compare to SAB Biotherapeutics?

Which has preferable valuation and earnings, DOMH or SABS?

Does the media favor DOMH or SABS?

Do analysts rate DOMH or SABS?

Which has more volatility & risk, DOMH or SABS?

Do insiders and institutionals hold more shares of DOMH or SABS?

Is DOMH or SABS more profitable?

Summary

How does Dominari compare to Agenus?

Does the media refer more to DOMH or AGEN?

Do institutionals and insiders have more ownership in DOMH or AGEN?

Which has more volatility & risk, DOMH or AGEN?

Do analysts prefer DOMH or AGEN?

Which has better earnings & valuation, DOMH or AGEN?

Is DOMH or AGEN more profitable?

Summary

How does Dominari compare to Fortress Biotech?

Is DOMH or FBIO more profitable?

Does the media prefer DOMH or FBIO?

Which has stronger valuation and earnings, DOMH or FBIO?

Do analysts prefer DOMH or FBIO?

Which has more risk & volatility, DOMH or FBIO?

Do insiders & institutionals hold more shares of DOMH or FBIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DOMH vs. The Competition

Dominari Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools